Knight Therapeutics Inc.
TSX:GUD.TODrug Manufacturers - Specialty & Generic
+$0.07 today
- Market cap
- $1.14B
- Beta
- 0.07
- P/E (TTM)
- 164.6
- EPS (TTM)
- $0.06
Volume 0.04M
Average 0.10M
GUD.TO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Knight Therapeutics Inc.TSX: GUD.TO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of CA$1.38M rose 36.5% year over year, behind the +189.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 52.8% from the prior quarter. Over 3 fiscal years it compounded at +62.6% a year.
Context
- Stock-based compensation amounted to 1.8% of revenue in FY2025, up 1.3 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +36.5% toward the trailing-twelve-month pace of +189.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
CAD · from the cash flow
- Latest · FY2025
- 8.11M CAD
- Year-over-year change
- +336.2%
- 4-year CAGR
- +27.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.11M | +336.2% |
| FY2024 | 2024-12-31 | 1.86M | -20.1% |
| FY2023 | 2023-12-31 | 2.33M | +23.3% |
| FY2022 | 2022-12-31 | 1.89M | -38.0% |
| FY2021 | 2021-12-31 | 3.05M | — |
Stock-Based Compensation vs competitors
How GUD.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +189.7% is the 2nd highest of 8, against a peer median of -14.8%.
- Stock-based compensation amounts to 1.3% of revenue for GUD.TO, versus a peer median of 2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$7.29M CAD | -36.7% | -24.4% | 2.3% | |
| LTM Mar 2026 | CA$6.84M CAD | +189.7% | +62.6% | 1.3% | |
| LTM Mar 2026 | CA$5.06M CAD | +220.3% | -44.8% | 1.6% | |
| LTM Mar 2026 | $4.38M USD | -55.0% | -25.6% | 1.7% | |
| LTM Mar 2026 | CA$4.35M CAD | +17.3% | +51.7% | 6.5% | |
| LTM Mar 2026 | CA$3.45M CAD | -36.6% | — | 1.3% | |
| LTM Mar 2026 | CA$2.35M CAD | -14.8% | +32.4% | 2.0% | |
| LTM Mar 2026 | $1.8M USD | +64.7% | +62.8% | 3.5% | |
| Peer median (excluding GUD.TO) | — | -14.8% | +4.0% | 2.0% | |
Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 15.68M | (29.89M) | (16.84M) | 4.33M | (5.37M) |
| Depreciation & Amortization | 47.92M | 62.62M | 50.4M | 53.11M | 56.57M |
| Deferred Income Tax | (7.64M) | (17.13M) | (9.13M) | (3.24M) | (3.81M) |
| Stock-Based Compensation | 3.05M | 1.89M | 2.33M | 1.86M | 8.11M |
| Change in Working Capital | 627K | (9.99M) | (28.01M) | (19.62M) | 1.89M |
| Accounts Receivables | 8.59M | (26.42M) | 5.58M | (10.29M) | (26.53M) |
| Inventory | (17.19M) | (11.43M) | 698K | (5.91M) | (17.82M) |
| Accounts Payables | 11.46M | 30.6M | (21.63M) | 632K | 42.11M |
| Other Working Capital | (2.23M) | (2.74M) | (12.66M) | (4.06M) | 4.14M |
| Other Non-Cash Items | (15.01M) | 32.98M | 37.19M | (154K) | 12.91M |
| Operating Cash Flow | 44.62M | 40.48M | 35.94M | 36.28M | 70.3M |
| Capital Expenditures | (224.18M) | (25.82M) | (9.96M) | (31.47M) | (1.91M) |
| Acquisitions (Net) | (220.35M) | 0 | 0 | 0 | (110.05M) |
| Purchases of Investments | (64.32M) | (185.47M) | (334.16M) | (162.57M) | (70.39M) |
| Sales of Investments | 180.54M | 150.54M | 345.47M | 196.12M | 112.43M |
| Other Investing Activities | 223.04M | (2.33M) | 18.99M | (14.12M) | 17.6M |
| Investing Cash Flow | (105.28M) | (63.08M) | 29.34M | 16.96M | (84.11M) |
| Debt Repayment | (14.19M) | 31.49M | (18.02M) | (18.05M) | 23.19M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 511K |
| Common Stock Repurchased | (64.42M) | (30.07M) | (53.48M) | (8.87M) | (6.35M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 297K | (4.18M) | (9.5M) | (6.62M) | (4.34M) |
| Financing Cash Flow | (78.31M) | 1.76M | (81M) | (33.54M) | 13.01M |
| Effect of Forex Changes | (4.66M) | 6.55M | 2.8M | 1.64M | (2.86M) |
| Net Change in Cash | (143.63M) | (14.28M) | (12.92M) | 21.35M | (3.66M) |
| Free Cash Flow | (179.57M) | 14.67M | 25.98M | 4.81M | 68.4M |
Knight Therapeutics Inc.
TSX:GUD.TO
Intrinsic Alpha fair value
Locked
Current Price
$11.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.